Taken together, these results demonstrate superior efficacy of IGF2-tagged GAA over GAA when used as lentiviral gene therapy to treat skeletal muscle pathology in a Pompe disease mouse model. The gene discussed is IGF2; the disease is glycogen storage disease II.